Lynparza (olaparib) vs Orserdu (elacestrant)
Lynparza (olaparib) vs Orserdu (elacestrant)
Lynparza (olaparib) is a PARP inhibitor used primarily to treat certain types of breast and ovarian cancers in patients with specific genetic mutations (BRCA1/2 or homologous recombination deficiency). It works by preventing cancer cells from repairing their DNA, leading to cell death. In contrast, Orserdu (elacestrant) is a selective estrogen receptor degrader (SERD) indicated for the treatment of estrogen receptor-positive (ER+) breast cancer, and it functions by degrading the estrogen receptor, thereby inhibiting the growth of breast cancer cells that require estrogen to grow. Patients should consult with their healthcare provider to determine which medication is appropriate for their specific cancer type, genetic profile, and overall health condition.
Difference between Lynparza and Orserdu
Metric | Lynparza (olaparib) | Orserdu (elacestrant) |
---|---|---|
Generic name | Olaparib | Elacestrant |
Indications | Ovarian, breast, pancreatic, and prostate cancer | ER+/HER2- advanced or metastatic breast cancer |
Mechanism of action | Poly (ADP-ribose) polymerase inhibitor | Estrogen receptor antagonist |
Brand names | Lynparza | Orserdu |
Administrative route | Oral | Oral |
Side effects | Anemia, nausea, fatigue, vomiting, neutropenia, respiratory infections | Nausea, vomiting, fatigue, decreased appetite, constipation |
Contraindications | Myelosuppression, pregnancy, renal impairment | Not specified; consult prescribing information |
Drug class | PARP inhibitor | Selective estrogen receptor degrader |
Manufacturer | AstraZeneca and Merck & Co. | Radiopharm Theranostics |
Efficacy
Lynparza (Olaparib) Efficacy in Breast Cancer
Lynparza (olaparib) is a targeted therapy known as a PARP inhibitor, which has shown efficacy in the treatment of certain types of breast cancer. Specifically, it has been approved for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously received chemotherapy. Clinical trials have demonstrated that olaparib significantly prolongs progression-free survival compared to standard chemotherapy in this patient population. The efficacy of Lynparza in breast cancer is closely associated with the presence of BRCA mutations, which are known to impair DNA repair mechanisms in tumor cells, making them particularly susceptible to PARP inhibitors.
In a pivotal phase III trial, patients treated with olaparib experienced a median progression-free survival of 7.0 months, compared to 4.2 months for those who received chemotherapy. Moreover, the response rate to olaparib was higher, indicating that a greater proportion of patients experienced tumor shrinkage. This evidence supports Lynparza's role in providing a targeted treatment option that can delay disease progression and potentially improve quality of life for patients with BRCA-mutated breast cancer.
Orserdu (Elacestrant) Efficacy in Breast Cancer
Orserdu (elacestrant) is a novel oral selective estrogen receptor degrader (SERD) that has shown promising efficacy in the treatment of estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer. Elacestrant is designed to bind to the estrogen receptor, causing its degradation and thus blocking the receptor's signaling pathways that promote tumor growth. It offers a new therapeutic option for patients who have progressed on prior endocrine therapy, including those with ESR1 mutations, which are associated with resistance to other forms of endocrine therapy.
Recent clinical trial data has indicated that Orserdu is effective in improving progression-free survival in patients with ER-positive, HER2-negative advanced or metastatic breast cancer. In a phase II study, patients treated with elacestrant showed a median progression-free survival that was superior to that of patients receiving standard endocrine therapies. The benefit of Orserdu was observed both in the overall population and in the subset of patients with ESR1 mutations. These findings suggest that elacestrant may provide a meaningful clinical benefit to patients who have limited treatment options due to resistance to other endocrine therapies.
Regulatory Agency Approvals
Lynparza
Orserdu
Access Lynparza or Orserdu today
If Lynparza or Orserdu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us